<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.3"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Eur J Pediatr</journal-id><journal-id journal-id-type="iso-abbrev">Eur J Pediatr</journal-id><journal-title-group><journal-title>European Journal of Pediatrics</journal-title></journal-title-group><issn pub-type="ppub">0340-6199</issn><issn pub-type="epub">1432-1076</issn><publisher><publisher-name>Springer Berlin Heidelberg</publisher-name><publisher-loc>Berlin/Heidelberg</publisher-loc></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">40410442</article-id><article-id pub-id-type="pmc">PMC12101995</article-id>
<article-id pub-id-type="publisher-id">6188</article-id><article-id pub-id-type="doi">10.1007/s00431-025-06188-4</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research</subject></subj-group></article-categories><title-group><article-title>Impact of COVID-19 on the epidemiology of severe sinogenic and otogenic infections and their intracranial complications</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Dimopoulou</surname><given-names>Dimitra</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Berikopoulou</surname><given-names>Maria M.</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Tsoliakos</surname><given-names>Ioannis</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Michos</surname><given-names>Athanasios</given-names></name><address><email>amichos@med.uoa.gr</email></address><xref ref-type="aff" rid="Aff2">2</xref></contrib><aff id="Aff1"><label>1</label>2nd Department of Pediatrics, &#x0201d;Aghia Sofia&#x0201d; Children&#x02019;s Hospital, Athens, Greece </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/04gnjpq42</institution-id><institution-id institution-id-type="GRID">grid.5216.0</institution-id><institution-id institution-id-type="ISNI">0000 0001 2155 0800</institution-id><institution>Division of Infectious Diseases, 1st Department of Pediatrics, </institution><institution>National and Kapodistrian University of Athens, Thivon and Papadiamantopoulou, </institution></institution-wrap>11527 Athens, Greece </aff></contrib-group><author-notes><fn fn-type="com"><p>Communicated by Tobias Tenenbaum</p></fn></author-notes><pub-date pub-type="epub"><day>24</day><month>5</month><year>2025</year></pub-date><pub-date pub-type="pmc-release"><day>24</day><month>5</month><year>2025</year></pub-date><pub-date pub-type="ppub"><year>2025</year></pub-date><volume>184</volume><issue>6</issue><elocation-id>359</elocation-id><history><date date-type="received"><day>25</day><month>2</month><year>2025</year></date><date date-type="rev-recd"><day>3</day><month>5</month><year>2025</year></date><date date-type="accepted"><day>12</day><month>5</month><year>2025</year></date></history><permissions><copyright-statement>&#x000a9; The Author(s) 2025</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p><bold>Open Access</bold> This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>.</license-p></license></permissions><abstract id="Abs1"><p id="Par1">This study aims to evaluate the impact of COVID-19 pandemic on the incidence, microbiological characteristics, management, and outcomes of mastoiditis and orbital cellulitis and their intracranial complications in pediatric patients. A retrospective observational study was conducted at the major pediatric hospital of Athens from 1/2018 to 12/2023. Pediatric patients (0&#x02013;16&#x000a0;years) diagnosed with mastoiditis, orbital cellulitis, and related complications were included. Data were collected across three periods: pre-pandemic (1/2018&#x02013;3/2020), during the pandemic (4/2020&#x02013;6/2021), and post-pandemic (7/2021&#x02013;12/2023). Statistical analyses compared demographic, clinical, and microbiological characteristics between the periods. A total of 176 cases were included (76 mastoiditis and 100 orbital cellulitis cases). The in-hospital incidence of both infections increased significantly post-pandemic compared to the period before the pandemic (mastoiditis: 5.5 vs.13.6 per 1000 admissions; orbital cellulitis: 4.8 vs. 21.8 per 1000 admissions, <italic>P</italic>&#x02009;&#x0003c;&#x02009;0.001). <italic>Streptococcus</italic> and <italic>Staphylococcus</italic> species predominated across the three periods. Median (IQR) age was not significantly different between the two periods among patients with mastoiditis (pre-pandemic: 5.6 (3.5) years vs. post-pandemic: 3.3 (3.4) years, <italic>P</italic>&#x02009;=&#x02009;0.12) and among patients with orbital cellulitis (pre-pandemic: 9.2 (6.6) years vs. post-pandemic: 8 (9.2) years, <italic>P</italic>&#x02009;=&#x02009;0.50). Regarding the complications, the rate of intracranial empyema/abscess development among patients with orbital cellulitis, but not mastoiditis, was lower post-pandemic compared to pre-pandemic (30% vs. 10.1%, <italic>P</italic>&#x02009;=&#x02009;0.03).</p><p id="Par2">
<italic>Conclusion</italic>: The study findings demonstrate a significant rise in the post-COVID-19 in-hospital incidence of mastoiditis and orbital cellulitis in children. Future epidemiological surveillance of these complications and pathogen-specific dynamics, are important to develop prevention strategies for these severe pediatric infections. 
<table-wrap id="Taba"><table frame="hsides" rules="groups"><tbody><tr><td align="left"><bold>What is Known:</bold></td></tr><tr><td align="left">&#x02022; <italic>The COVID-19 pandemic shifted the epidemiology of severe upper respiratory tract infections.</italic></td></tr><tr><td align="left">&#x02022; <italic>Data on the epidemiology of severe sinogenic and otogenic infections and their intracranial complications during and after the acute phase of the COVID-19 pandemic are limited in Europe.</italic></td></tr><tr><td align="left"><bold>What is New:</bold></td></tr><tr><td align="left">&#x02022; <italic>This study highlights a notable increase in the in-hospital incidence of mastoiditis and orbital cellulitis during the post-COVID-19 pandemic era, likely associated with immunity debt and alterations in respiratory microbiota.</italic></td></tr><tr><td align="left">&#x02022; <italic>Despite the increase in pediatric mastoiditis and orbital cellulitis cases, the rates of complications and surgical management remained stable throughout the study period.</italic></td></tr></tbody></table></table-wrap></p><sec><title>Supplementary Information</title><p>The online version contains supplementary material available at 10.1007/s00431-025-06188-4.</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Mastoiditis</kwd><kwd>Orbital cellulitis</kwd><kwd>Children</kwd><kwd>COVID-19</kwd><kwd>Intracranial infections</kwd><kwd>Empyema</kwd><kwd>Sinogenic infections</kwd><kwd>Otogenic infections</kwd></kwd-group><funding-group><award-group><funding-source><institution>University of Athens</institution></funding-source></award-group><open-access><p>Open access funding provided by HEAL-Link Greece.</p></open-access></funding-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; Springer-Verlag GmbH Germany, part of Springer Nature 2025</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Introduction</title><p id="Par13">Upper respiratory tract infections (URIs), including acute otitis media, sinusitis, and their complications, mastoiditis and orbital cellulitis, are very common in children [<xref ref-type="bibr" rid="CR1">1</xref>]. The incidence of mastoiditis in developed countries ranges from 1.2 to 4.2 per 100,000 children per year, whereas the one of orbital cellulitis is estimated around 1.6 per 100,000 children per year [<xref ref-type="bibr" rid="CR2">2</xref>&#x02013;<xref ref-type="bibr" rid="CR4">4</xref>]. Despite the potential for serious complications, a broad-spectrum intravenous antibiotic treatment seems to be an effective treatment [<xref ref-type="bibr" rid="CR5">5</xref>, <xref ref-type="bibr" rid="CR6">6</xref>].</p><p id="Par14">Intracranial infections (IIs), including epidural and intraparenchymal abscesses, epidural and subdural empyemas, are more rare but serious complications of acute otitis media, sinusitis, mastoiditis and orbital cellulitis [<xref ref-type="bibr" rid="CR7">7</xref>]. Intracranial infections are more common in children and young adults resulting in significant morbidity and mortality [<xref ref-type="bibr" rid="CR8">8</xref>, <xref ref-type="bibr" rid="CR9">9</xref>]. Anaerobic and microaerophilic streptococci, such as the <italic>Streptococcus milleri</italic> group (<italic>Streptococcus anginosus</italic> or <italic>Streptococcus intermedius</italic>) are the main cause of IIs. However, some of these infections are multimicrobial [<xref ref-type="bibr" rid="CR7">7</xref>, <xref ref-type="bibr" rid="CR10">10</xref>]. Treatment typically requires neurosurgical and otolaryngological interventions accompanied by antibiotics. In most cases, early diagnosis and adequate treatment lead to good outcome [<xref ref-type="bibr" rid="CR11">11</xref>].</p><p id="Par15">Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) caused a global pandemic with significant morbidity and mortality [<xref ref-type="bibr" rid="CR12">12</xref>]. The pandemic shifted the epidemiology of URIs, including mastoiditis, with a dropping incidence, followed by an increase after the lockdown [<xref ref-type="bibr" rid="CR13">13</xref>, <xref ref-type="bibr" rid="CR14">14</xref>]. However, since the onset of COVID-19 pandemic, the frequency of intracranial pyogenic complications has significantly increased [<xref ref-type="bibr" rid="CR15">15</xref>]. In 2022, the Center for Disease Control and Prevention (CDC) noted an increase of intracranial complications in the USA. During 2021&#x02013;2022, more streptococci-related intracranial empyema or abscess were reported. Another study in the USA, also, reported a 236% increase of infectious intracranial complications [<xref ref-type="bibr" rid="CR16">16</xref>, <xref ref-type="bibr" rid="CR17">17</xref>].</p><p id="Par16">Data on the epidemiology of severe sinogenic and otogenic infections and their intracranial complications during and after the acute phase of the COVID-19 pandemic are limited in Europe. The purpose of this study is to evaluate the impact of COVID-19 pandemic on epidemiology and characteristics of severe infections, such as mastoiditis and orbital cellulitis and their complications.</p></sec><sec id="Sec2"><title>Materials and methods</title><p id="Par17">A retrospective observational study was carried out at &#x0201c;Aghia Sophia&#x0201d; Children&#x02019;s Hospital in Athens, from January 1&#x02009;st, 2018, to December 31 st, 2023. This is the largest tertiary pediatric hospital in Greece (750 beds), serving approximately 40% of the pediatric population in the Athens metropolitan area and severe cases of regional hospitals.</p><p id="Par18">The study population consisted of all children aged 0&#x02013;16 years old, who were hospitalized with mastoiditis, orbital cellulitis and otogenic or sinogenic intracranial complications at &#x0201c;Aghia Sophia&#x0201d; Children&#x02019;s General Hospital in Athens (Neurosurgery and Otorhinolaryngology departments) during the study period.</p><p id="Par19">Mastoiditis, orbital cellulitis cases and their complications were identified by search for all the relevant ICD-10 (International Classification of Diseases) codes. More specifically, mastoiditis cases were identified by &#x00397;70.0, H70.1, H70.8, H70.9, H70, H74, H74.8, H74.9, H95 and orbital cellulitis cases by H05, H05.0, H05.8. Data from patients&#x02019; records, including patients&#x02019; demographic information, medical history, risk factors, clinical presentation, surgical management, microbiology results, antibiotic treatment, duration of the treatment, complications, and outcomes, were also recorded. Patients with chronic sinusitis&#x02013;otitis&#x02013;mastoiditis and the presence of cerebrospinal fluid (CSF) shunt-related infections were excluded.</p><p id="Par20">In Greece, the first COVID-19 patient was diagnosed on 26 February 2020 and educational institutions were closed in March 2020. Stricter measures were implemented, leading to a general lockdown on 23 March 2020. Following a second wave of the pandemic, schools eventually reopened in April 2021 [<xref ref-type="bibr" rid="CR18">18</xref>]. Based on the timeline of lockdown restrictions and school closures, the study period was divided into three subperiods: before (January 2018&#x02013;March 2020, period 1), during (April 2020&#x02013;June 2021, period 2), and after (July 2021&#x02013;December 2023, period 3) the COVID-19 lockdown. In order to calculate the in-hospital incidence of mastoiditis and orbital cellulitis, hospital admission data by department (Neurosurgery and Otorhinolaryngology departments) were collected.</p><p id="Par21">The study was approved by the institution&#x02019;s Ethical and Research Committee (approval protocol number: 2936&#x02013;02/02/24) and all procedures were conducted in accordance with the 1964 Declaration of Helsinki and its later amendments.</p><p id="Par22">For statistical analysis, <italic>x</italic><sup>2</sup> test or Fisher&#x02019;s exact test was used to compare data between the study subperiods. An analysis with <italic>t</italic>-test was conducted to compare the continuous data between the three periods. Statistical significance was set at 0.05. Statistical analysis was conducted using SAS (v 9.4) statistical analysis software.</p></sec><sec id="Sec3"><title>Results</title><p id="Par23">A total of 176 pediatric patients with a median age of 5.65 years old (range: 0.5&#x02013;15.7 years) with the diagnosis of mastoiditis or orbital cellulitis were enrolled in the study across the three different periods; 43 patients during the pre-pandemic period (Period 1: January 2018&#x02013;March 2020), 21 during the COVID-19 pandemic (Period 2: April 2020&#x02013;June 2021), and 112 during the post-pandemic period (Period 3: July 2021&#x02013;December 2023).</p><p id="Par24">During the study period, 76 cases of mastoiditis [Period 1: 23 cases (30.3%); Period 2: 10 cases (13.1%); Period 3: 43 cases (56.6%)] and 100 cases of orbital cellulitis [Period 1: 20 cases (20%); Period 2: 11 cases (11%); Period 3: 69 cases (69%)] were identified. A more detailed semester-based trend of mastoiditis and orbital cellulitis cases (N) over the six-year study period is presented in Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>A and B. The majority of these cases were managed in the Otorhinolaryngology Department, which accounted for 70 mastoiditis and 98 orbital cellulitis cases. Comparing the in-hospital incidence of mastoiditis cases across the three periods, statistically significant difference was detected (<italic>P</italic>&#x02009;&#x0003c; 0.001) (Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>). The same trend was observed in the in-hospital incidence of orbital cellulitis cases across the three periods (<italic>P</italic>&#x02009;&#x0003c; 0.001) (Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>).<fig id="Fig1"><label>Fig. 1</label><caption><p><bold>&#x00391;</bold> Number of patients with mastoiditis during the 3 study periods [Period 1 (pre-pandemic): January 2018&#x02013;March 2020, Period 2 (during pandemic): April 2020&#x02013;June 2021, and Period 3 (post-pandemic): July 2021&#x02013;December 2023], <bold>&#x00392;</bold> Number of patients with orbital cellulitis during the 3 study periods [Period 1 (pre-pandemic): January 2018&#x02013;March 2020, Period 2 (during pandemic): April 2020&#x02013;June 2021, and Period 3 (post-pandemic): July 2021&#x02013;December 2023]</p></caption><graphic xlink:href="431_2025_6188_Fig1_HTML" id="MO1"/></fig><table-wrap id="Tab1"><label>Table 1</label><caption><p>Distribution of diagnosed cases of mastoiditis (N =&#x02009;76) and orbital cellulitis (N =&#x02009;100) admitted to the Neurosurgery and Otorhinolaryngology Departments during the 3 study periods [Period 1 (pre-pandemic): January 2018&#x02013;March 2020, Period 2 (during pandemic): April 2020&#x02013;June 2021, and Period 3 (post-pandemic): July 2021&#x02013;December 2023]</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="2">Periods</th><th align="left" rowspan="2">Admissions<break/>N (%)</th><th align="left" colspan="3">Mastoiditis</th><th align="left" colspan="3">Orbital cellulitis</th></tr><tr><th align="left">&#x0039d; (%)</th><th align="left">&#x02030; of hospital admissions</th><th align="left"><italic>P</italic>-value</th><th align="left">&#x0039d; (%)</th><th align="left">&#x02030; of hospital admissions</th><th align="left"><italic>P</italic>-value</th></tr></thead><tbody><tr><td align="left"><p>Period1</p><p>(pre-pandemic)</p></td><td align="left">4152 (45.7)</td><td align="left">23 (30.3)</td><td char="." align="char">5.5</td><td align="left" rowspan="3"><bold>&#x02009;&#x0003c; 0.001</bold></td><td align="left">20 (20.0)</td><td char="." align="char">4.8</td><td align="left" rowspan="3"><bold>&#x02009;&#x0003c; 0.001</bold></td></tr><tr><td align="left"><p>Period 2</p><p>(during pandemic)</p></td><td align="left">1762 (19.4)</td><td align="left">10 (13.1)</td><td char="." align="char">5.7</td><td align="left">11 (11.0)</td><td char="." align="char">6.2</td></tr><tr><td align="left"><p>Period 3</p><p>(post-pandemic)</p></td><td align="left">3165 (34.9)</td><td align="left">43 (56.6)</td><td char="." align="char">13.6</td><td align="left">69 (69.0)</td><td char="." align="char">21.8</td></tr><tr><td align="left">Total</td><td align="left">9079 (100.0)</td><td align="left">76 (100.0)</td><td char="." align="char">8.3</td><td align="left"/><td align="left">100 (100.0)</td><td char="." align="char">11.0</td><td align="left"/></tr></tbody></table></table-wrap></p><p id="Par25">The in-hospital incidence of mastoiditis cases rose significantly during the post-pandemic period, from a rate of 5.5 per 1000 hospital admissions pre-COVID-19 pandemic compared to 13.6 per 1000 hospital admissions in the post-pandemic period (<italic>P</italic>&#x02009;&#x0003c; 0.001) (Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>, Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>). In addition, cases with orbital cellulitis increased significantly pre-pandemic from 4.8 per 1000 hospital admissions to 21.8 per 1000 hospital admissions in the post-pandemic period (<italic>P</italic>&#x02009;&#x0003c; 0.001) (Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>, Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>). The in-hospital incidence of mastoiditis and orbital cellulitis cases was low during the pandemic (5.7 and 6.2 per 1000 hospital admissions, respectively) (Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>, Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>). A more detailed figure of in-hospital incidence of mastoiditis and orbital cellulitis over the six-year study period is presented in Supplementary Fig. <xref rid="MOESM1" ref-type="media">S1</xref>.<fig id="Fig2"><label>Fig. 2</label><caption><p>Distribution of the in-hospital incidence of cases with mastoiditis and orbital cellulitis (cases per 1000 hospital admissions) during the 3 study periods [Period 1 (pre-pandemic): January 2018&#x02013;March 2020, Period 2 (during pandemic): April 2020&#x02013;June 2021, and Period 3 (post-pandemic): July 2021&#x02013;December 2023]</p></caption><graphic xlink:href="431_2025_6188_Fig2_HTML" id="MO2"/></fig></p><p id="Par26">Demographics and clinical characteristics of the patients diagnosed with mastoiditis during the pre- and post-pandemic period are described in the Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref>. A higher proportion of male patients was noted in the post-pandemic period (74.4%) compared to pre-pandemic (34.8%, <italic>P</italic>&#x02009;= 0.002). Age was not significantly different between the two periods (Median (IQR) pre-pandemic: 5.6 (3.5) years vs. post-pandemic: 3.3 (3.4) years, <italic>P</italic>&#x02009;= 0.12).
<table-wrap id="Tab2"><label>Table 2</label><caption><p>Demographics and clinical characteristics of patients with mastoiditis (N =&#x02009;66) during the pre- (January 2018&#x02013;March 2020) and post-pandemic period (July 2021&#x02013;December 2023)</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Characteristics<break/>&#x0039d; =&#x02009;66</th><th align="left">Pre-pandemic period (N =&#x02009;23)<break/>N (%)</th><th align="left">Post-pandemic period (N =&#x02009;43)<break/>N (%)</th><th align="left"><italic>P</italic>-value</th></tr></thead><tbody><tr><td align="left">Sex (male/female)</td><td align="left">8/15 (34.8/65.2)</td><td align="left">32/11 (74.4/25.6)</td><td align="left"><bold>0.002</bold></td></tr><tr><td align="left">Age [median (IQR)] (years)</td><td align="left">5.6 (3.5)</td><td align="left">3.3 (3.4)</td><td align="left">0.12</td></tr><tr><td align="left">Previous antimicrobial administration</td><td align="left">11(47.8)</td><td align="left">17 (39.5)</td><td align="left">0.52</td></tr><tr><td align="left" colspan="4">Laboratory investigations</td></tr><tr><td align="left"><p>WBC [mean (SD)] (/mm<sup>3</sup>)</p><p>Neutrophils [mean (SD)] (/mm<sup>3</sup>)</p><p>Lymphocytes [mean (SD)] (/mm<sup>3</sup>)</p><p>CRP [mean (SD)] (mg/L)</p></td><td align="left"><p>14,029 (8943)</p><p>9817 (8165)</p><p>2850 (1585)</p><p>106.6 (89.2)</p></td><td align="left"><p>16,949 (6277)</p><p>10,702 (4193)</p><p>3867 (1956)</p><p>97.4 (68.4)</p></td><td align="left"><p>0.13</p><p>0.63</p><p><bold>0.04</bold></p><p>0.64</p></td></tr><tr><td align="left">Children on antibiotic treatment before purulent sample</td><td align="left">9 (39.1)</td><td align="left">14 (32.5)</td><td align="left">0.6</td></tr><tr><td align="left">Positive pus culture</td><td align="left">5 (21.7)</td><td align="left">20 (46.5)</td><td align="left"><bold>0.048</bold></td></tr><tr><td align="left">Complications (total)</td><td align="left">8 (34.8)</td><td align="left">12 (27.9)</td><td align="left">0.43</td></tr><tr><td align="left"><p>Cerebral venous sinus thrombosis</p><p>Intracranial empyema/abscess</p><p>Facial nerve palsy</p></td><td align="left"><p>4 (17.4)</p><p>3 (13.0)</p><p>1 (4.3)</p></td><td align="left"><p>6 (13.9)</p><p>4 (9.3)</p><p>2 (4.6)</p></td><td align="left"><p>0.71</p><p>0.69</p><p>0.95</p></td></tr><tr><td align="left">Surgery</td><td align="left">20 (87.0)</td><td align="left">34 (79.1)</td><td align="left">0.52</td></tr><tr><td align="left">Duration of hospitalization (days) [mean (SD)]</td><td align="left">11.7 (5.8)</td><td align="left">10.6 (3.8)</td><td align="left">0.40</td></tr></tbody></table></table-wrap></p><p id="Par27">Also, there was no statistically significant difference in the previous antibiotic use among patients with mastoiditis (47.8% pre-pandemic vs. 39.5% post-pandemic, <italic>P</italic>&#x02009;= 0.52). The laboratory findings between the pre- and post-pandemic periods, such as white blood cell count (WBC) and C-reactive protein (CRP) levels were not statistically significantly different.</p><p id="Par28">Regarding complications, including mainly cerebral venous sinus thrombosis and intracranial abscesses, there was no significant difference between pre-pandemic (8/23, 34.8%) and post-pandemic period (11/43, 25.6%) among patients with mastoiditis (<italic>P</italic>&#x02009;= 0.43). Surgical intervention was required in 79.1% of mastoiditis cases post-pandemic, with no statistically significant difference in the rates across periods (87.0% pre-pandemic vs. 79.1% post-pandemic, <italic>P</italic>&#x02009;= 0.52). The average duration of hospitalization for mastoiditis decreased from 11.7 days pre-pandemic to 10.6 days post-pandemic (<italic>P</italic>&#x02009;= 0.40).</p><p id="Par29">Demographics and clinical characteristics of the patients diagnosed with orbital cellulitis during the pre- and post-pandemic period are described in the Table&#x000a0;<xref rid="Tab3" ref-type="table">3</xref>. During the pre-pandemic period, 70% of cases were males compared to 56.5% during the post-pandemic period (<italic>P</italic>&#x02009;= 0.28). Median (IQR) age was not significantly different between the two periods (pre-pandemic: 9.2 (6.6) years vs. post-pandemic: 8 (9.2) years, <italic>P</italic>&#x02009;= 0.50).
<table-wrap id="Tab3"><label>Table 3</label><caption><p>Demographics and clinical characteristics of patients with orbital cellulitis (N =&#x02009;89) during the pre- (January 2018&#x02013;March 2020) and post-pandemic period (July 2021&#x02013;December 2023)</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Characteristics<break/>&#x0039d; =&#x02009;89</th><th align="left">Pre-pandemic period (N =&#x02009;20)<break/>N (%)</th><th align="left">Post-pandemic period (N =&#x02009;69)<break/>N (%)</th><th align="left"><italic>P</italic>-value</th></tr></thead><tbody><tr><td align="left">Sex (male/female)</td><td align="left">14/6 (70.0/30.0)</td><td align="left">39/30 (56.5/43.5)</td><td align="left">0.28</td></tr><tr><td align="left">Age [median (IQR)] (years)</td><td align="left">9.2 (6.6)</td><td align="left">8 (9.2)</td><td align="left">0.50</td></tr><tr><td align="left">Previous antimicrobial administration</td><td align="left">8(40.0)</td><td align="left">23 (33.3)</td><td align="left">0.58</td></tr><tr><td align="left" colspan="4">Laboratory investigations</td></tr><tr><td align="left"><p>WBC [mean (SD)] (/mm<sup>3</sup>)</p><p>Neutrophils [mean (SD)] (/mm<sup>3</sup>)</p><p>Lymphocytes [mean (SD)] (/mm<sup>3</sup>)</p><p>CRP [mean (SD)] (mg/L)</p></td><td align="left"><p>13,559 (5514)</p><p>8782 (4210)</p><p>3093 (2935)</p><p>83.6 (105.9)</p></td><td align="left"><p>14,161 (5440)</p><p>9580 (5117)</p><p>2977 (2224)</p><p>63.3 (50.8)</p></td><td align="left"><p>0.67</p><p>0.53</p><p>0.85</p><p>0.41</p></td></tr><tr><td align="left">Children on antibiotic treatment before purulent sample</td><td align="left">2 (10)</td><td align="left">3 (4.4)</td><td align="left">0.31</td></tr><tr><td align="left">Positive pus culture</td><td align="left">4 (20.0)</td><td align="left">4 (5.8)</td><td align="left">0.07</td></tr><tr><td align="left">Complications (total)</td><td align="left">6 (30.0)</td><td align="left">9 (13.0)</td><td align="left">0.09</td></tr><tr><td align="left"><p>Intracranial empyema/abscess</p><p>Optic neuritis</p><p>Pott&#x02019;s tumor</p></td><td align="left"><p>6 (30.0)</p><p>0</p><p>0</p></td><td align="left"><p>7 (10.1)</p><p>1 (1.4)</p><p>1 (1.4)</p></td><td align="left"><p><bold>0.03</bold></p><p>0.59</p><p>0.59</p></td></tr><tr><td align="left">Surgery</td><td align="left">6 (30.0)</td><td align="left">9 (13.0)</td><td align="left">0.09</td></tr><tr><td align="left">Duration of hospitalization (days) [mean (SD)]</td><td align="left">9.8 (7.1)</td><td align="left">8.1 (3.9)</td><td align="left">0.29</td></tr></tbody></table></table-wrap></p><p id="Par30">There was no statistically significant difference in the previous antibiotic use among patients with orbital cellulitis (40% pre-pandemic vs. 33.3% post-pandemic, <italic>P</italic>&#x02009;= 0.58). Also, there was no significant difference in the laboratory findings between the two different periods, such as WBC and CRP levels (mean (SD) WBC: 13,559 (5514)/mm<sup>3</sup> pre-pandemic vs. 14,161 (5440)/mm<sup>3</sup> post-pandemic, <italic>P</italic>&#x02009;= 0.67 and mean (SD) CRP: 83.6 (105.9) mg/L pre-pandemic vs. 63.3 (50.8) mg/L post-pandemic, <italic>P</italic>&#x02009;= 0.41).</p><p id="Par31">Regarding the complications rates, they were higher in the pre-pandemic period, however, there were not statistically significant differences, with the exception of intracranial empyemas/abscesses development among patients with orbital cellulitis, which were lower post-pandemic compared to pre-pandemic (6/20, 30% vs. 8/69, 10.1%, <italic>P</italic>&#x02009;= 0.03). Surgical intervention was performed in 13% of post-pandemic cases, which is lower than the pre-pandemic rate of 30% (<italic>P</italic>&#x02009;= 0.09). Of note, there were no significant age differences who underwent surgical intervention post-pandemic compared to pre-pandemic. Specifically, the mean age of children requiring surgery during the post-pandemic period was 6.1 years (SD: 4.75) compared to 7.8 years during the pre-pandemic (SD: 4.08) (<italic>P</italic>&#x02009;= 0.12). Finally, hospitalization duration was comparable, with mean durations of 8.1 days post-pandemic and 9.8 days pre-pandemic (<italic>P</italic>&#x02009;= 0.29).</p><p id="Par32">In patients with mastoiditis, positive pus culture results increased significantly after the pandemic, from 21.7% pre-pandemic to 46.5% post-pandemic (<italic>P</italic>&#x02009;= 0.048) (Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref>). Regarding the pathogens isolated from the pus cultures obtained from the patients with mastoiditis and orbital cellulitis during the three periods are reported in the Table&#x000a0;<xref rid="Tab4" ref-type="table">4</xref>. <italic>Staphylococcus</italic> spp. and <italic>Streptococcus</italic> spp. were the most frequently isolated pathogens in patients with mastoiditis, with an increase in polymicrobial infections, including anaerobic and gram-negative bacteria during the post-pandemic period (Table&#x000a0;<xref rid="Tab4" ref-type="table">4</xref>). In patients with orbital cellulitis, a decrease in positive pus cultures was observed post-pandemic (20% pre-pandemic vs. 5.8% post-pandemic, <italic>P</italic>&#x02009;= 0.07) (Table&#x000a0;<xref rid="Tab3" ref-type="table">3</xref>). Patients with orbital cellulitis displayed higher polymicrobial infections post-pandemic, primarily involving <italic>Staphylococcus</italic> spp. and <italic>Streptococcus</italic> spp. in combination with anaerobic and gram-negative bacteria (Table&#x000a0;<xref rid="Tab4" ref-type="table">4</xref>).
<table-wrap id="Tab4"><label>Table 4</label><caption><p>Pathogens isolated from the pus cultures obtained from the patients with orbital cellulitis (N =&#x02009;8) and mastoiditis (N =&#x02009;25) during the pre- (January 2018&#x02013;March 2020) and post-pandemic period (July 2021&#x02013;December 2023)</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="2">Isolated pathogens</th><th align="left" colspan="2">Orbital cellulitis</th><th align="left" colspan="2">Mastoiditis</th></tr><tr><th align="left">Pre-pandemic period (N =&#x02009;4)<break/>N (%)</th><th align="left">Post-pandemic period (N =&#x02009;4)<break/>N (%)</th><th align="left">Pre-pandemic period (N =&#x02009;5)<break/>N (%)</th><th align="left">Post-pandemic period (N =&#x02009;20)<break/>N (%)</th></tr></thead><tbody><tr><td align="left">Monomicrobial infection</td><td align="left">3 (75)</td><td align="left">1 (25)</td><td align="left">4 (80)</td><td align="left">11(55)</td></tr><tr><td align="left">Polymicrobial infection</td><td align="left">1(25)</td><td align="left">3 (75)</td><td align="left">1(20)</td><td align="left">9 (45)</td></tr><tr><td align="left"><italic>Streptococcus anginosus</italic>, <italic>Streptococcus mitis</italic>, Coagulase negative <italic>Staphylococcus</italic>, Gram (+) anaerobic rods</td><td align="left">N/A</td><td align="left">N/A</td><td align="left">0</td><td align="left">1 (11.1)</td></tr><tr><td align="left"><italic>Streptococcus anginosus</italic>, Coagulase negative <italic>Staphylococcus</italic>, Gram (+) anaerobic rods</td><td align="left">N/A</td><td align="left">N/A</td><td align="left">0</td><td align="left">1 (11.1)</td></tr><tr><td align="left"><italic>Streptococcus pyogenes</italic>, Coagulase negative <italic>Staphylococcus</italic>, Gram (+) anaerobic rods</td><td align="left">N/A</td><td align="left">N/A</td><td align="left">0</td><td align="left">2 (22.2)</td></tr><tr><td align="left">Coagulase negative <italic>Staphylococcus</italic>, Gram (&#x02212;) anaerobic rods</td><td align="left">N/A</td><td align="left">N/A</td><td align="left">0</td><td align="left">1 (11.1)</td></tr><tr><td align="left"><italic>Streptococcus pyogenes</italic>, Coagulase negative <italic>Staphylococcus</italic></td><td align="left">1 (100)</td><td align="left">0</td><td align="left">0</td><td align="left">1 (11.1)</td></tr><tr><td align="left"><italic>Streptococcus pneumoniae</italic>, Coagulase negative <italic>Staphylococcus</italic></td><td align="left">N/A</td><td align="left">N/A</td><td align="left">1 (100)</td><td align="left">1 (11.1)</td></tr><tr><td align="left"><italic>Streptococcus pneumoniae</italic>, <italic>Haemophilus</italic> spp.</td><td align="left">N/A</td><td align="left">N/A</td><td align="left">0</td><td align="left">1 (11.1)</td></tr><tr><td align="left"><italic>Pseudomonas</italic> spp. Gram (&#x02212; anaerobic rods</td><td align="left">N/A</td><td align="left">N/A</td><td align="left">0</td><td align="left">1 (11.1)</td></tr><tr><td align="left"><italic>Klebsiella</italic> spp. Gram (+) anaerobic rods, Gram (&#x02212;) anaerobic cocci</td><td align="left">0</td><td align="left">1 (33.3)</td><td align="left">N/A</td><td align="left">N/A</td></tr><tr><td align="left"><italic>Streptococcus anginosus</italic>, <italic>Streptococcus pneumoniae</italic>, Gram (+) anaerobic cocci</td><td align="left">0</td><td align="left">1 (33.3)</td><td align="left">N/A</td><td align="left">N/A</td></tr><tr><td align="left"><italic>Streptococcus mitis</italic>, Coagulase negative <italic>Staphylococcus</italic>,<italic> Micrococcus luteus</italic></td><td align="left">0</td><td align="left">1 (33.3)</td><td align="left">N/A</td><td align="left">N/A</td></tr><tr><td align="left" colspan="5">Type of microorganism</td></tr><tr><td align="left"><italic>Staphylococcus aureus</italic></td><td align="left">0</td><td align="left">1 (25)</td><td align="left">0</td><td align="left">3 (15)</td></tr><tr><td align="left">Coagulase negative<italic> Staphylococcus</italic></td><td align="left">3 (75)</td><td align="left">1 (25)</td><td align="left">2 (40)</td><td align="left">10 (50)</td></tr><tr><td align="left"><italic>Streptococcus pneumoniae</italic></td><td align="left">0</td><td align="left">1 (25)</td><td align="left">1 (20)</td><td align="left">2 (10)</td></tr><tr><td align="left"><italic>Streptococcus anginosus group</italic></td><td align="left">0</td><td align="left">1 (25)</td><td align="left">0</td><td align="left">3 (15)</td></tr><tr><td align="left"><italic>Streptococcus mitis</italic></td><td align="left">0</td><td align="left">1 (25)</td><td align="left">1 (20)</td><td align="left">1 (5)</td></tr><tr><td align="left"><italic>Streptococcus pyogenes</italic></td><td align="left">1 (25)</td><td align="left">0</td><td align="left">1 (20)</td><td align="left">3 (15)</td></tr><tr><td align="left">Gram (+) anaerobic rods</td><td align="left">0</td><td align="left">1 (25)</td><td align="left">0</td><td align="left">5 (25)</td></tr><tr><td align="left">Gram (+) anaerobic cocci</td><td align="left">1 (25)</td><td align="left">1 (25)</td><td align="left">N/A</td><td align="left">N/A</td></tr><tr><td align="left">Gram (&#x02212;) anaerobic rods</td><td align="left">N/A</td><td align="left">N/A</td><td align="left">0</td><td align="left">1 (5)</td></tr><tr><td align="left">Gram (&#x02212;) anaerobic cocci</td><td align="left">0</td><td align="left">1 (25)</td><td align="left">N/A</td><td align="left">N/A</td></tr><tr><td align="left"><italic>Klebsiella</italic> spp.</td><td align="left">0</td><td align="left">1 (25)</td><td align="left">N/A</td><td align="left">N/A</td></tr><tr><td align="left"><italic>Micrococcus luteus</italic></td><td align="left">0</td><td align="left">1 (25)</td><td align="left">N/A</td><td align="left">N/A</td></tr><tr><td align="left"><italic>Pseudomonas</italic> spp.</td><td align="left">N/A</td><td align="left">N/A</td><td align="left">1 (20)</td><td align="left">1 (5)</td></tr><tr><td align="left"><italic>Haemophilus</italic> spp.</td><td align="left">N/A</td><td align="left">N/A</td><td align="left">0</td><td align="left">1 (5)</td></tr><tr><td align="left"><italic>Enterococcus</italic> spp.</td><td align="left">N/A</td><td align="left">N/A</td><td align="left">0</td><td align="left">2 (10)</td></tr></tbody></table></table-wrap></p></sec><sec id="Sec4"><title>Discussion</title><p id="Par33">In the present study, we evaluated the impact of COVID-19 pandemic on the epidemiology and characteristics of mastoiditis and orbital cellulitis and their complications in children. A significant increase in the in-hospital incidence of mastoiditis and orbital cellulitis cases during the post-pandemic period was observed compared to the period before and during the pandemic. Indeed, a study from Germany showed a rise in the acute mastoiditis cases in children aged mainly 1&#x02013;5 years old at the end of COVID-19 pandemic after the reduction of non-pharmaceutical interventions (NPI), compared to pre-pandemic period (2011&#x02013;2019) [<xref ref-type="bibr" rid="CR19">19</xref>]. In addition, another study from Germany showed a tenfold increase in acute pediatric mastoiditis after COVID-19 restrictions [<xref ref-type="bibr" rid="CR20">20</xref>].</p><p id="Par34">Several studies showed a decrease of the total pediatric admissions related to the head and neck infections, including mastoiditis, sinusitis and orbital cellulitis, following the implementation of COVID-19 restrictions, with no significant difference in mean age patient, admission duration and surgical rates [<xref ref-type="bibr" rid="CR21">21</xref>]. Furthermore, a study involving 8 pediatric hospitals of the USA from March 2020 to March 2022 observed a decrease of orbital cellulitis, sinusitis and mastoiditis by 14.5%, 31.9% and 24.7%, respectively [<xref ref-type="bibr" rid="CR22">22</xref>]. A national observational study in the UK showed a decreased incidence in pediatric acute mastoiditis during the post-COVID-19 period (December 2020&#x02013;February 2021) in comparison to the pre-COVID-19 period, possibly due to the loss of upper respiratory tract infections driven winter peak in infection [<xref ref-type="bibr" rid="CR14">14</xref>]. However, this reduction in the cases of mastoiditis and orbital cellulitis may be due to the fact that these studies were conducted during the implementation of COVID-19 restrictions and the early period after the removal of these measures.</p><p id="Par35">In the present study, the total complication rates were higher in the pre-pandemic period, however, there were not statistically significant differences, with the exception of intracranial abscesses and empyemas following orbital cellulitis, but not mastoiditis, which decreased during the post-COVID-19 compared to the pre-pandemic period. In addition, the rate of intracranial empyemas was 9.3% and 10.1% in the children with mastoiditis and orbital cellulitis during the post-pandemic period, which are in line with previous studies ranging from 4 to 16% during the pre-COVID-19 era [<xref ref-type="bibr" rid="CR23">23</xref>, <xref ref-type="bibr" rid="CR24">24</xref>]. Similarly, one study by Goldberg-Bockhorn et al. demonstrated a complication rate of 13% in children with mastoiditis and a trend toward a slow increase of complications during the post-pandemic period, but this change was not significant [<xref ref-type="bibr" rid="CR19">19</xref>]. In contrast, another study from the USA showed that mastoiditis complicated by intracranial abscess decreased by 116.7% [<xref ref-type="bibr" rid="CR22">22</xref>]. In addition, several studies have reported a notable increase in the epidemiology of pediatric sinogenic and otogenic intracranial complications during and after the COVID-19 pandemic, which may be related to the indirect effects of COVID-19 [<xref ref-type="bibr" rid="CR10">10</xref>, <xref ref-type="bibr" rid="CR16">16</xref>, <xref ref-type="bibr" rid="CR25">25</xref>, <xref ref-type="bibr" rid="CR26">26</xref>].</p><p id="Par36">Also, it has been shown a slight rise in the incidence of septic cerebral venous sinus thrombosis in the setting of pediatric sinogenic and otogenic intracranial infections during the COVID-19 pandemic [<xref ref-type="bibr" rid="CR27">27</xref>]. Our findings revealed that there was no significant difference in surgery rates and duration of hospitalization pre- and post-COVID-19 era, which are in line with other studies, which indicated a decrease in surgeries among pediatric patients with acute mastoiditis or other complicated upper respiratory infections during the pandemic, but during the subsequent years after the pandemic, the surgery rate reached to pre-pandemic levels as well as a similar morbidity and mortality rate between the different periods [<xref ref-type="bibr" rid="CR14">14</xref>, <xref ref-type="bibr" rid="CR19">19</xref>, <xref ref-type="bibr" rid="CR26">26</xref>]. Several possible associations between the COVID-19 pandemic and the complicated infections of the upper respiratory infections have been described [<xref ref-type="bibr" rid="CR25">25</xref>]. COVID-19 infection has been associated with a range of immunological complications and various secondary bacterial infections [<xref ref-type="bibr" rid="CR28">28</xref>].</p><p id="Par37">Non-pharmaceutical interventions such as social distancing, universal mask-wearing, and implementation of lockdown measures were implied in the onset of the pandemic, leading to a phenomenon called &#x0201c;immunity debt&#x0201d; [<xref ref-type="bibr" rid="CR29">29</xref>]. According to this theory, the lack of active immunization against common endemic pathogens for an extended period due to non-exposure, leads to reduced immune memory. This may result in an increased frequency and severity of infections globally, such as the case of respiratory syncytial virus [<xref ref-type="bibr" rid="CR29">29</xref>&#x02013;<xref ref-type="bibr" rid="CR31">31</xref>]. Whether the &#x0201c;immunity debt&#x0201d; caused this sudden increase in the frequency of paranasal sinusitis and other infections is yet to be confirmed. Other theory proposes the disruption of the respiratory microbiota and replacement with more virulent bacterial species, as well as the immune dysregulation and mucosal barrier dysfunction may be some of the mechanisms that can result in severe complicated infections of the upper respiratory infections, such as mastoiditis and orbital cellulitis in children [<xref ref-type="bibr" rid="CR25">25</xref>].</p><p id="Par38">Regarding pathogen identification, recent reports presented a notable increase of <italic>Streptococcus intermedius</italic> and other <italic>Streptococcus anginosus</italic> group species among the pediatric patients with sinogenic or otogenic intracranial purulent infections after the COVID-19 pandemic [<xref ref-type="bibr" rid="CR15">15</xref>]. More specifically, in the USA, after a decline in cases with streptococcal intracranial infections at the onset of the COVID-19 pandemic, cases increased and peaked in March 2022 and then declined to baseline levels. <italic>S. imtermedius</italic> was the most prevalent isolated microorganism, followed by <italic>S. anginosus</italic> and <italic>S. constellatus</italic> [<xref ref-type="bibr" rid="CR17">17</xref>]. Thus, clinical presentation and microbiological features were stable during the pre- and post-COVID-19 era, and there was no evidence of increased case severity, increased antimicrobial resistance or genetic relatedness of streptococcal isolates [<xref ref-type="bibr" rid="CR17">17</xref>]. Another study showed a rise in pediatric sinusitis or otitis related intracranial infections, with <italic>S. imtermedius</italic>, <italic>S. anginosus</italic> and <italic>S. constellatus</italic> being more prevalent isolated microorganisms [<xref ref-type="bibr" rid="CR25">25</xref>]. An additional study demonstrated that among sinogenic abscesses in children, <italic>S. imtermedius</italic> was the most prevalent, while among otogenic ones, <italic>S. pyogenes</italic> was the most common microorganism [<xref ref-type="bibr" rid="CR32">32</xref>]. However, one study conducted before the onset of pandemic reported that the incidence of <italic>S. anginosus</italic>-related infections and particularly, complicated sinusitis increased 12% per year from 2010 to 2016 [<xref ref-type="bibr" rid="CR33">33</xref>].</p><p id="Par39">Therefore, the increased cases of <italic>S. anginosus</italic> group species infections in children after the pandemic may be due to seasonal fluctuations and a redistribution of cases over time and may result from changes in antimicrobial prescribing practices and in nasopharyngeal colonization due to childhood vaccinations, rather than to the effects of the COVID-19 pandemic only. Two studies from Germany evaluating acute mastoiditis in children before, during and after COVID-19 restrictions noted that there were no significant differences in pathogen distribution between the periods, with <italic>S. pneumoniae</italic> and <italic>S. pyogenes</italic> being the most commonly isolated microorganisms [<xref ref-type="bibr" rid="CR19">19</xref>, <xref ref-type="bibr" rid="CR20">20</xref>]. In our study, <italic>Streptococcus</italic> spp. and <italic>Staphylococcus</italic> spp. were more frequently isolated pathogens, with no significant difference between the study periods. However, several purulent samples were obtained after the administration of antimicrobials, which could have affected culture results and identifications of specific bacteria. Also, coagulase negative <italic>Staphyloccoci</italic> (CoNS) are often considered contaminants, particularly in cases involving non-sterile sites or inappropriate specimen collection techniques and the potential role of CoNS identification in clinical samples should be interpreted with caution.</p><p id="Par40">&#x003a4;his study has certain limitations, as this is a single center retrospective study and some data, such as the vaccination status of children, were not available. Detailed information regarding the specific types of surgical procedures performed was not available. Furthermore, the findings may have been impacted by changes in healthcare professionals&#x02019; practices and clinical experience during the study period and therefore, decision-making and criteria applied for surgical management may be different across the three periods. Additionally, the observed decline in the total number of hospital admissions during the post-pandemic period may reflect system-level changes in healthcare delivery and patient referral patterns and may limit the generalizability of the results. Finally, PCR analysis was not performed to the purulent samples in the current study and this may limit the ability to detect certain pathogens, reducing the diagnostic accuracy. However, this is the first report about the impact of COVID-19 on the epidemiology of mastoiditis and orbital cellulitis in the Greek pediatric population. The data covers a long period (pre-, during and post-COVID-19) in the largest children&#x02019;s hospital of Greece and the referral pediatric center for the majority of cases of central and southern country, which could be representative of the general population.</p><p id="Par41">In conclusion, this study highlights a notable increase in the in-hospital incidence of mastoiditis and orbital cellulitis during the post-COVID-19 pandemic era, likely associated with factors such as immunity debt and alterations in respiratory microbiota. Despite the increase in pediatric mastoiditis and orbital cellulitis cases, the rates of complications and surgical management remained stable throughout the study period. These findings underscore the need to recognize the indirect effects of the pandemic on severe pediatric infectious diseases and their management. Further prospective, multicenter, international studies should focus on longitudinal monitoring of these trends to confirm the long-term impact of COVID-19 on these infections in the pediatric population, in order to provide new insights into these growing epidemiological patterns, evaluate pathogen-specific dynamics and develop new preventive strategies to diminish the burden of these severe pediatric infections and their complications in the post-pandemic era.</p></sec><sec id="Sec5" sec-type="supplementary-material"><title>Supplementary Information</title><p>Below is the link to the electronic supplementary material.<supplementary-material content-type="local-data" id="MOESM1"><media xlink:href="431_2025_6188_MOESM1_ESM.docx"><caption><p>Supplementary file1 (DOCX 393 KB)</p></caption></media></supplementary-material></p></sec></body><back><glossary><title>Abbreviations</title><def-list><def-item><term>CDC</term><def><p id="Par3">Center for Disease Control and Prevention</p></def></def-item><def-item><term>CSF</term><def><p id="Par4">Cerebrospinal fluid</p></def></def-item><def-item><term>ICD-10</term><def><p id="Par5">International Classification of Diseases</p></def></def-item><def-item><term>IIs</term><def><p id="Par6">Intracranial Infections</p></def></def-item><def-item><term>NPI</term><def><p id="Par7">Non-pharmaceutical interventions</p></def></def-item><def-item><term>SARS-CoV-2</term><def><p id="Par8">Severe acute respiratory syndrome coronavirus 2</p></def></def-item><def-item><term><italic>S. anginosus</italic></term><def><p id="Par9">
<italic>Streptococcus</italic>
<italic>anginosus</italic>
</p></def></def-item><def-item><term><italic>S. constellatus</italic></term><def><p id="Par10">
<italic>Streptococcus constellatus</italic>
</p></def></def-item><def-item><term><italic>S. imtermedius</italic></term><def><p id="Par11">
<italic>Streptococcus intermedious</italic>
</p></def></def-item><def-item><term>URIs</term><def><p id="Par12">Upper respiratory tract infections</p></def></def-item></def-list></glossary><fn-group><fn><p><bold>Publisher's Note</bold></p><p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn></fn-group><notes notes-type="author-contribution"><title>Author contributions</title><p>All authors contributed to the study conception and design. D.D. and A.M. contributed to the conception and design of the work. Material preparation and data collection were performed by D.D., M.M.B., I.T. Data analysis was performed by D.D. and A.M. The first draft of the manuscript was written by D.D. and M.M.B and all authors commented on previous versions of the manuscript. All authors read and approved the final manuscript.</p></notes><notes notes-type="funding-information"><title>Funding</title><p>Open access funding provided by HEAL-Link Greece.</p></notes><notes notes-type="data-availability"><title>Data availability</title><p>No datasets were generated or analysed during the current study.</p></notes><notes><title>Declarations</title><notes id="FPar1"><title>Ethics approval</title><p id="Par42">The study was approved by the &#x0201c;Aghia Sophia&#x0201d; Children&#x02019;s Hospital&#x02019;s Ethical and Research Committee (approval number: 2936&#x02013;02/02/24). All procedures were conducted in accordance with the 1964 Declaration of Helsinki and its later amendments.</p></notes><notes id="FPar2"><title>Consent to participate</title><p id="Par43">For all participants written informed consent was obtained from the parents at the time of the enrollment.</p></notes><notes id="FPar3"><title>Consent for publication</title><p id="Par44">Not applicable.</p></notes><notes id="FPar4" notes-type="COI-statement"><title>Competing interests</title><p id="Par45">The authors declare no competing interests.</p></notes></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><mixed-citation publication-type="other">Cinaroglu S (2020) Prevalence of upper respiratory tract infections and associated factors among children in Turkey. J Specialists Pediatr Nurs 25. 10.1111/jspn.12276</mixed-citation></ref><ref id="CR2"><label>2.</label><citation-alternatives><element-citation id="ec-CR2" publication-type="journal"><person-group person-group-type="author"><name><surname>Pelletier</surname><given-names>J</given-names></name><name><surname>Koyfman</surname><given-names>A</given-names></name><name><surname>Long</surname><given-names>B</given-names></name></person-group><article-title>High risk and low prevalence diseases: orbital cellulitis</article-title><source>Am J Emerg Med</source><year>2023</year><volume>68</volume><fpage>1</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1016/j.ajem.2023.02.024</pub-id><pub-id pub-id-type="pmid">36893591</pub-id>
</element-citation><mixed-citation id="mc-CR2" publication-type="journal">Pelletier J, Koyfman A, Long B (2023) High risk and low prevalence diseases: orbital cellulitis. Am J Emerg Med 68:1&#x02013;9<pub-id pub-id-type="pmid">36893591</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR3"><label>3.</label><citation-alternatives><element-citation id="ec-CR3" publication-type="journal"><person-group person-group-type="author"><name><surname>Samuel</surname><given-names>O</given-names></name><name><surname>Saliba</surname><given-names>W</given-names></name><name><surname>Stein</surname><given-names>N</given-names></name><etal/></person-group><article-title>Epidemiology of pediatric acute mastoiditis in Israel: a National Registry 10-year perspective</article-title><source>Laryngoscope Investig Otolaryngol</source><year>2022</year><volume>7</volume><fpage>2139</fpage><lpage>2144</lpage><pub-id pub-id-type="doi">10.1002/lio2.948</pub-id><pub-id pub-id-type="pmid">36544929</pub-id>
</element-citation><mixed-citation id="mc-CR3" publication-type="journal">Samuel O, Saliba W, Stein N et al (2022) Epidemiology of pediatric acute mastoiditis in Israel: a National Registry 10-year perspective. Laryngoscope Investig Otolaryngol 7:2139&#x02013;2144. 10.1002/lio2.948<pub-id pub-id-type="pmid">36544929</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR4"><label>4.</label><citation-alternatives><element-citation id="ec-CR4" publication-type="journal"><person-group person-group-type="author"><name><surname>Tawfik</surname><given-names>KO</given-names></name><name><surname>Ishman</surname><given-names>SL</given-names></name><name><surname>Tabangin</surname><given-names>ME</given-names></name><etal/></person-group><article-title>Pediatric acute mastoiditis in the era of pneumococcal vaccination</article-title><source>Laryngoscope</source><year>2018</year><volume>128</volume><fpage>1480</fpage><lpage>1485</lpage><pub-id pub-id-type="doi">10.1002/lary.26968</pub-id><pub-id pub-id-type="pmid">29105776</pub-id>
</element-citation><mixed-citation id="mc-CR4" publication-type="journal">Tawfik KO, Ishman SL, Tabangin ME et al (2018) Pediatric acute mastoiditis in the era of pneumococcal vaccination. Laryngoscope 128:1480&#x02013;1485. 10.1002/lary.26968<pub-id pub-id-type="pmid">29105776</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR5"><label>5.</label><citation-alternatives><element-citation id="ec-CR5" publication-type="journal"><person-group person-group-type="author"><name><surname>Anosike</surname><given-names>BI</given-names></name><name><surname>Ganapathy</surname><given-names>V</given-names></name><name><surname>Nakamura</surname><given-names>MM</given-names></name></person-group><article-title>Epidemiology and management of orbital cellulitis in children</article-title><source>J Pediatric Infect Dis Soc</source><year>2022</year><volume>11</volume><fpage>214</fpage><lpage>220</lpage><pub-id pub-id-type="doi">10.1093/jpids/piac006</pub-id><pub-id pub-id-type="pmid">35438766</pub-id>
</element-citation><mixed-citation id="mc-CR5" publication-type="journal">Anosike BI, Ganapathy V, Nakamura MM (2022) Epidemiology and management of orbital cellulitis in children. J Pediatric Infect Dis Soc 11:214&#x02013;220. 10.1093/jpids/piac006<pub-id pub-id-type="pmid">35438766</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR6"><label>6.</label><citation-alternatives><element-citation id="ec-CR6" publication-type="journal"><person-group person-group-type="author"><name><surname>Mierzwi&#x00144;ski</surname><given-names>J</given-names></name><name><surname>Tyra</surname><given-names>J</given-names></name><name><surname>Haber</surname><given-names>K</given-names></name><etal/></person-group><article-title>Therapeutic approach to pediatric acute mastoiditis &#x02013; an update</article-title><source>Braz J Otorhinolaryngol</source><year>2019</year><volume>85</volume><fpage>724</fpage><lpage>732</lpage><pub-id pub-id-type="doi">10.1016/j.bjorl.2018.06.002</pub-id><pub-id pub-id-type="pmid">30056031</pub-id>
</element-citation><mixed-citation id="mc-CR6" publication-type="journal">Mierzwi&#x00144;ski J, Tyra J, Haber K et al (2019) Therapeutic approach to pediatric acute mastoiditis &#x02013; an update. Braz J Otorhinolaryngol 85:724&#x02013;732. 10.1016/j.bjorl.2018.06.002<pub-id pub-id-type="pmid">30056031</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR7"><label>7.</label><citation-alternatives><element-citation id="ec-CR7" publication-type="journal"><person-group person-group-type="author"><name><surname>McNeil</surname><given-names>JC</given-names></name><name><surname>Dunn</surname><given-names>JJ</given-names></name><name><surname>Kaplan</surname><given-names>SL</given-names></name><name><surname>Vallejo</surname><given-names>JG</given-names></name></person-group><article-title>Complications of otitis media and sinusitis caused by Streptococcus anginosus group organisms in children</article-title><source>Pediatric Infectious Disease Journal</source><year>2020</year><volume>39</volume><fpage>108</fpage><lpage>113</lpage><pub-id pub-id-type="doi">10.1097/INF.0000000000002514</pub-id><pub-id pub-id-type="pmid">31738321</pub-id>
</element-citation><mixed-citation id="mc-CR7" publication-type="journal">McNeil JC, Dunn JJ, Kaplan SL, Vallejo JG (2020) Complications of otitis media and sinusitis caused by Streptococcus anginosus group organisms in children. Pediatric Infectious Disease Journal 39:108&#x02013;113. 10.1097/INF.0000000000002514<pub-id pub-id-type="pmid">31738321</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR8"><label>8.</label><citation-alternatives><element-citation id="ec-CR8" publication-type="journal"><person-group person-group-type="author"><name><surname>De Bonis</surname><given-names>P</given-names></name><name><surname>Anile</surname><given-names>C</given-names></name><name><surname>Pompucci</surname><given-names>A</given-names></name><etal/></person-group><article-title>Cranial and spinal subdural empyema</article-title><source>Br J Neurosurg</source><year>2009</year><volume>23</volume><fpage>335</fpage><lpage>340</lpage><pub-id pub-id-type="doi">10.1080/02688690902939902</pub-id><pub-id pub-id-type="pmid">19533473</pub-id>
</element-citation><mixed-citation id="mc-CR8" publication-type="journal">De Bonis P, Anile C, Pompucci A et al (2009) Cranial and spinal subdural empyema. Br J Neurosurg 23:335&#x02013;340<pub-id pub-id-type="pmid">19533473</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR9"><label>9.</label><mixed-citation publication-type="other">Nathoo N, Nadvi SS, van Dellen JR, Gouws E (1999) Intracranial subdural empyemas in the era of computed tomography: a review of 699 cases. Neurosurgery 44:529&#x02013;35; discussion 535&#x02013;6.10.1097/00006123-199903000-00055</mixed-citation></ref><ref id="CR10"><label>10.</label><citation-alternatives><element-citation id="ec-CR10" publication-type="journal"><person-group person-group-type="author"><name><surname>Hall</surname><given-names>BJ</given-names></name><name><surname>Duddy</surname><given-names>JC</given-names></name><name><surname>Apostolopoulou</surname><given-names>K</given-names></name><etal/></person-group><article-title>Intracranial empyemas in the COVID-19 era: a new phenomenon? A paediatric case series and review of the literature</article-title><source>Pediatr Neurosurg</source><year>2023</year><volume>58</volume><fpage>215</fpage><lpage>222</lpage><pub-id pub-id-type="doi">10.1159/000531753</pub-id><pub-id pub-id-type="pmid">37393893</pub-id>
</element-citation><mixed-citation id="mc-CR10" publication-type="journal">Hall BJ, Duddy JC, Apostolopoulou K et al (2023) Intracranial empyemas in the COVID-19 era: a new phenomenon? A paediatric case series and review of the literature. Pediatr Neurosurg 58:215&#x02013;222. 10.1159/000531753<pub-id pub-id-type="pmid">37393893</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR11"><label>11.</label><citation-alternatives><element-citation id="ec-CR11" publication-type="journal"><person-group person-group-type="author"><name><surname>Morgan</surname><given-names>E</given-names></name><name><surname>Nwadiokwu</surname><given-names>JI</given-names></name><name><surname>Olowo</surname><given-names>S</given-names></name><etal/></person-group><article-title>A review of the current management of intracranial infections of neurosurgical importance</article-title><source>West Afr J Med</source><year>2024</year><volume>41</volume><fpage>135</fpage><lpage>147</lpage><pub-id pub-id-type="pmid">38581674</pub-id>
</element-citation><mixed-citation id="mc-CR11" publication-type="journal">Morgan E, Nwadiokwu JI, Olowo S et al (2024) A review of the current management of intracranial infections of neurosurgical importance. West Afr J Med 41:135&#x02013;147<pub-id pub-id-type="pmid">38581674</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR12"><label>12</label><citation-alternatives><element-citation id="ec-CR12" publication-type="journal"><person-group person-group-type="author"><name><surname>Iezadi</surname><given-names>S</given-names></name><name><surname>Gholipour</surname><given-names>K</given-names></name><name><surname>Azami-Aghdash</surname><given-names>S</given-names></name><etal/></person-group><article-title>Effectiveness of non-pharmaceutical public health interventions against COVID-19: a systematic review and meta-analysis</article-title><source>PLoS One</source><year>2021</year><volume>16</volume><fpage>e0260371</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0260371</pub-id><pub-id pub-id-type="pmid">34813628</pub-id>
</element-citation><mixed-citation id="mc-CR12" publication-type="journal">Iezadi S, Gholipour K, Azami-Aghdash S et al (2021) Effectiveness of non-pharmaceutical public health interventions against COVID-19: a systematic review and meta-analysis. PLoS One 16:e0260371<pub-id pub-id-type="pmid">34813628</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR13"><label>13.</label><mixed-citation publication-type="other">Zhu Y, Li W, Yang B, et al (2021) Epidemiological and virological characteristics of respiratory tract infections in children during COVID-19 outbreak. BMC Pediatr 21.10.1186/s12887-021-02654-8</mixed-citation></ref><ref id="CR14"><label>14.</label><citation-alternatives><element-citation id="ec-CR14" publication-type="journal"><person-group person-group-type="author"><name><surname>Smith</surname><given-names>ME</given-names></name><name><surname>Jones</surname><given-names>GH</given-names></name><name><surname>Hardman</surname><given-names>JC</given-names></name><etal/></person-group><article-title>Acute paediatric mastoiditis in the UK before and during the COVID-19 pandemic: a national observational study</article-title><source>Clin Otolaryngol</source><year>2022</year><volume>47</volume><fpage>120</fpage><lpage>130</lpage><pub-id pub-id-type="doi">10.1111/coa.13869</pub-id><pub-id pub-id-type="pmid">34606691</pub-id>
</element-citation><mixed-citation id="mc-CR14" publication-type="journal">Smith ME, Jones GH, Hardman JC et al (2022) Acute paediatric mastoiditis in the UK before and during the COVID-19 pandemic: a national observational study. Clin Otolaryngol 47:120&#x02013;130. 10.1111/coa.13869<pub-id pub-id-type="pmid">34606691</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR15"><label>15.</label><citation-alternatives><element-citation id="ec-CR15" publication-type="journal"><person-group person-group-type="author"><name><surname>Syrogiannopoulos</surname><given-names>GA</given-names></name><name><surname>Michoula</surname><given-names>AN</given-names></name><name><surname>Syrogiannopoulou</surname><given-names>TG</given-names></name><name><surname>Anthracopoulos</surname><given-names>MB</given-names></name></person-group><article-title>Streptococcus intermedius and other Streptococcus anginosus Group species in pediatric cranial and intracranial pyogenic infections</article-title><source>Pediatr Infect Dis J</source><year>2024</year><volume>43</volume><fpage>e92</fpage><lpage>e95</lpage><pub-id pub-id-type="doi">10.1097/INF.0000000000004182</pub-id><pub-id pub-id-type="pmid">38011035</pub-id>
</element-citation><mixed-citation id="mc-CR15" publication-type="journal">Syrogiannopoulos GA, Michoula AN, Syrogiannopoulou TG, Anthracopoulos MB (2024) Streptococcus intermedius and other Streptococcus anginosus Group species in pediatric cranial and intracranial pyogenic infections. Pediatr Infect Dis J 43:e92&#x02013;e95. 10.1097/INF.0000000000004182<pub-id pub-id-type="pmid">38011035</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR16"><label>16.</label><citation-alternatives><element-citation id="ec-CR16" publication-type="journal"><person-group person-group-type="author"><name><surname>Massimi</surname><given-names>L</given-names></name><name><surname>Cinalli</surname><given-names>G</given-names></name><name><surname>Frassanito</surname><given-names>P</given-names></name><etal/></person-group><article-title>Intracranial complications of sinogenic and otogenic infections in children: an ESPN survey on their occurrence in the pre-COVID and post-COVID era</article-title><source>Childs Nerv Syst</source><year>2024</year><volume>40</volume><fpage>1221</fpage><lpage>1237</lpage><pub-id pub-id-type="doi">10.1007/s00381-024-06332-9</pub-id><pub-id pub-id-type="pmid">38456922</pub-id>
</element-citation><mixed-citation id="mc-CR16" publication-type="journal">Massimi L, Cinalli G, Frassanito P et al (2024) Intracranial complications of sinogenic and otogenic infections in children: an ESPN survey on their occurrence in the pre-COVID and post-COVID era. Childs Nerv Syst 40:1221&#x02013;1237. 10.1007/s00381-024-06332-9<pub-id pub-id-type="pmid">38456922</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR17"><label>17.</label><mixed-citation publication-type="other">Accorsi EK, Chochua S, Moline HL, et al (2022) Pediatric brain abscesses, epidural empyemas, and subdural empyemas associated with Streptococcus species - United States, January 2016-August 2022. MMWR Morb Mortal Wkly Rep 71:1169&#x02013;1173.10.15585/mmwr.mm7137a2</mixed-citation></ref><ref id="CR18"><label>18.</label><citation-alternatives><element-citation id="ec-CR18" publication-type="journal"><person-group person-group-type="author"><name><surname>Dimopoulou</surname><given-names>D</given-names></name><name><surname>Kyritsi</surname><given-names>M</given-names></name><name><surname>Dadouli</surname><given-names>K</given-names></name><etal/></person-group><article-title>Seroprevalence of anti-SARS-CoV-2 antibodies among children and their parents in Greece</article-title><source>Eur J Pediatr</source><year>2022</year><volume>182</volume><fpage>439</fpage><lpage>449</lpage><pub-id pub-id-type="doi">10.1007/s00431-022-04681-8</pub-id><pub-id pub-id-type="pmid">36383284</pub-id>
</element-citation><mixed-citation id="mc-CR18" publication-type="journal">Dimopoulou D, Kyritsi M, Dadouli K et al (2022) Seroprevalence of anti-SARS-CoV-2 antibodies among children and their parents in Greece. Eur J Pediatr 182:439&#x02013;449. 10.1007/s00431-022-04681-8<pub-id pub-id-type="pmid">36383284</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR19"><label>19.</label><citation-alternatives><element-citation id="ec-CR19" publication-type="journal"><person-group person-group-type="author"><name><surname>Goldberg-Bockhorn</surname><given-names>E</given-names></name><name><surname>Hurzlmeier</surname><given-names>C</given-names></name><name><surname>Vahl</surname><given-names>JM</given-names></name><etal/></person-group><article-title>Increase in acute mastoiditis at the end of the COVID-19 pandemic</article-title><source>Eur Arch Otorhinolaryngol</source><year>2024</year><volume>281</volume><fpage>4747</fpage><lpage>4756</lpage><pub-id pub-id-type="doi">10.1007/s00405-024-08704-y</pub-id><pub-id pub-id-type="pmid">38740579</pub-id>
</element-citation><mixed-citation id="mc-CR19" publication-type="journal">Goldberg-Bockhorn E, Hurzlmeier C, Vahl JM et al (2024) Increase in acute mastoiditis at the end of the COVID-19 pandemic. Eur Arch Otorhinolaryngol 281:4747&#x02013;4756. 10.1007/s00405-024-08704-y<pub-id pub-id-type="pmid">38740579</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR20"><label>20.</label><citation-alternatives><element-citation id="ec-CR20" publication-type="journal"><person-group person-group-type="author"><name><surname>Draut</surname><given-names>S</given-names></name><name><surname>M&#x000fc;ller</surname><given-names>J</given-names></name><name><surname>Hempel</surname><given-names>J-M</given-names></name><etal/></person-group><article-title>Tenfold increase: acute pediatric mastoiditis before, during, and after COVID-19 restrictions</article-title><source>Otol Neurotol</source><year>2024</year><volume>45</volume><fpage>777</fpage><lpage>782</lpage><pub-id pub-id-type="doi">10.1097/MAO.0000000000004238</pub-id><pub-id pub-id-type="pmid">38956778</pub-id>
</element-citation><mixed-citation id="mc-CR20" publication-type="journal">Draut S, M&#x000fc;ller J, Hempel J-M et al (2024) Tenfold increase: acute pediatric mastoiditis before, during, and after COVID-19 restrictions. Otol Neurotol 45:777&#x02013;782. 10.1097/MAO.0000000000004238<pub-id pub-id-type="pmid">38956778</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR21"><label>21.</label><citation-alternatives><element-citation id="ec-CR21" publication-type="journal"><person-group person-group-type="author"><name><surname>Urichuk</surname><given-names>M</given-names></name><name><surname>Azzi</surname><given-names>JL</given-names></name><name><surname>Leitao</surname><given-names>DJ</given-names></name></person-group><article-title>The impact of COVID-19 restrictions on hospital admissions of common head and neck infections</article-title><source>Laryngoscope</source><year>2024</year><volume>134</volume><fpage>3542</fpage><lpage>3547</lpage><pub-id pub-id-type="doi">10.1002/lary.31366</pub-id><pub-id pub-id-type="pmid">38415842</pub-id>
</element-citation><mixed-citation id="mc-CR21" publication-type="journal">Urichuk M, Azzi JL, Leitao DJ (2024) The impact of COVID-19 restrictions on hospital admissions of common head and neck infections. Laryngoscope 134:3542&#x02013;3547. 10.1002/lary.31366<pub-id pub-id-type="pmid">38415842</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR22"><label>22.</label><mixed-citation publication-type="other">Khuon D, Ogrin S, Engels J, et al (2022) Notes from the field: increase in pediatric intracranial infections during the COVID-19 pandemic - eight pediatric hospitals, United States, March 2020-March 2022. MMWR Morb Mortal Wkly Rep 71:1000&#x02013;1001.10.15585/mmwr.mm7131a4</mixed-citation></ref><ref id="CR23"><label>23.</label><citation-alternatives><element-citation id="ec-CR23" publication-type="journal"><person-group person-group-type="author"><name><surname>Cassano</surname><given-names>P</given-names></name><name><surname>Ciprandi</surname><given-names>G</given-names></name><name><surname>Passali</surname><given-names>D</given-names></name></person-group><article-title>Acute mastoiditis in children</article-title><source>Acta Biomed</source><year>2020</year><volume>91</volume><fpage>54</fpage><lpage>59</lpage><pub-id pub-id-type="doi">10.23750/abm.v91i1-S.9259</pub-id><pub-id pub-id-type="pmid">32073562</pub-id>
</element-citation><mixed-citation id="mc-CR23" publication-type="journal">Cassano P, Ciprandi G, Passali D (2020) Acute mastoiditis in children. Acta Biomed 91:54&#x02013;59. 10.23750/abm.v91i1-S.9259<pub-id pub-id-type="pmid">32073562</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR24"><label>24.</label><citation-alternatives><element-citation id="ec-CR24" publication-type="journal"><person-group person-group-type="author"><name><surname>Favre</surname><given-names>N</given-names></name><name><surname>Patel</surname><given-names>VA</given-names></name><name><surname>Carr</surname><given-names>MM</given-names></name></person-group><article-title>Complications in pediatric acute mastoiditis: HCUP KID analysis</article-title><source>Otolaryngol Head Neck Surg</source><year>2021</year><volume>165</volume><fpage>722</fpage><lpage>730</lpage><pub-id pub-id-type="doi">10.1177/0194599821989633</pub-id><pub-id pub-id-type="pmid">33588620</pub-id>
</element-citation><mixed-citation id="mc-CR24" publication-type="journal">Favre N, Patel VA, Carr MM (2021) Complications in pediatric acute mastoiditis: HCUP KID analysis. Otolaryngol Head Neck Surg 165:722&#x02013;730. 10.1177/0194599821989633<pub-id pub-id-type="pmid">33588620</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR25"><label>25.</label><citation-alternatives><element-citation id="ec-CR25" publication-type="journal"><person-group person-group-type="author"><name><surname>Angelo</surname><given-names>SJ</given-names></name><name><surname>Anderson</surname><given-names>MG</given-names></name><name><surname>Sutter</surname><given-names>PA</given-names></name><etal/></person-group><article-title>Changes in the epidemiology of pediatric sinogenic and otogenic intracranial infections during the COVID-19 pandemic: a single-institution study</article-title><source>J Neurosurg Pediatr</source><year>2023</year><volume>32</volume><fpage>231</fpage><lpage>241</lpage><pub-id pub-id-type="doi">10.3171/2023.4.PEDS23130</pub-id><pub-id pub-id-type="pmid">37243559</pub-id>
</element-citation><mixed-citation id="mc-CR25" publication-type="journal">Angelo SJ, Anderson MG, Sutter PA et al (2023) Changes in the epidemiology of pediatric sinogenic and otogenic intracranial infections during the COVID-19 pandemic: a single-institution study. J Neurosurg Pediatr 32:231&#x02013;241. 10.3171/2023.4.PEDS23130<pub-id pub-id-type="pmid">37243559</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR26"><label>26.</label><citation-alternatives><element-citation id="ec-CR26" publication-type="journal"><person-group person-group-type="author"><name><surname>Metz</surname><given-names>C</given-names></name><name><surname>Schmid</surname><given-names>A</given-names></name><name><surname>Veldhoen</surname><given-names>S</given-names></name></person-group><article-title>Increase in complicated upper respiratory tract infection in children during the 2022/2023 winter season-a post coronavirus disease 2019 effect?</article-title><source>Pediatr Radiol</source><year>2024</year><volume>54</volume><fpage>49</fpage><lpage>57</lpage><pub-id pub-id-type="doi">10.1007/s00247-023-05808-1</pub-id><pub-id pub-id-type="pmid">37999795</pub-id>
</element-citation><mixed-citation id="mc-CR26" publication-type="journal">Metz C, Schmid A, Veldhoen S (2024) Increase in complicated upper respiratory tract infection in children during the 2022/2023 winter season-a post coronavirus disease 2019 effect? Pediatr Radiol 54:49&#x02013;57. 10.1007/s00247-023-05808-1<pub-id pub-id-type="pmid">37999795</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR27"><label>27.</label><citation-alternatives><element-citation id="ec-CR27" publication-type="journal"><person-group person-group-type="author"><name><surname>Sutter</surname><given-names>PA</given-names></name><name><surname>Anderson</surname><given-names>MG</given-names></name><name><surname>Sahyouni</surname><given-names>R</given-names></name><etal/></person-group><article-title>Anticoagulation for the treatment of septic cerebral venous sinus thrombosis in the setting of pediatric sinogenic and otogenic intracranial infections</article-title><source>Neurosurg Focus</source><year>2023</year><volume>55</volume><fpage>E8</fpage><pub-id pub-id-type="doi">10.3171/2023.7.FOCUS23374</pub-id><pub-id pub-id-type="pmid">37778041</pub-id>
</element-citation><mixed-citation id="mc-CR27" publication-type="journal">Sutter PA, Anderson MG, Sahyouni R et al (2023) Anticoagulation for the treatment of septic cerebral venous sinus thrombosis in the setting of pediatric sinogenic and otogenic intracranial infections. Neurosurg Focus 55:E8. 10.3171/2023.7.FOCUS23374<pub-id pub-id-type="pmid">37778041</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR28"><label>28.</label><mixed-citation publication-type="other">Farrell JM, Zhao CY, Tarquinio KM, Brown SP (2021) Causes and consequences of COVID-19-associated bacterial infections. Front Microbiol 12.10.3389/fmicb.2021.682571</mixed-citation></ref><ref id="CR29"><label>29</label><citation-alternatives><element-citation id="ec-CR29" publication-type="journal"><person-group person-group-type="author"><name><surname>Cohen</surname><given-names>R</given-names></name><name><surname>Levy</surname><given-names>C</given-names></name><name><surname>Rybak</surname><given-names>A</given-names></name><etal/></person-group><article-title>Immune debt: recrudescence of disease and confirmation of a contested concept</article-title><source>Infect Dis Now</source><year>2023</year><volume>53</volume><fpage>104638</fpage><pub-id pub-id-type="doi">10.1016/j.idnow.2022.12.003</pub-id><pub-id pub-id-type="pmid">36535583</pub-id>
</element-citation><mixed-citation id="mc-CR29" publication-type="journal">Cohen R, Levy C, Rybak A et al (2023) Immune debt: recrudescence of disease and confirmation of a contested concept. Infect Dis Now 53:104638<pub-id pub-id-type="pmid">36535583</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR30"><label>30.</label><citation-alternatives><element-citation id="ec-CR30" publication-type="journal"><person-group person-group-type="author"><name><surname>Billard</surname><given-names>MN</given-names></name><name><surname>Bont</surname><given-names>LJ</given-names></name></person-group><article-title>Quantifying the RSV immunity debt following COVID-19: a public health matter</article-title><source>Lancet Infect Dis</source><year>2023</year><volume>23</volume><fpage>3</fpage><lpage>5</lpage><pub-id pub-id-type="doi">10.1016/S1473-3099(22)00544-8</pub-id><pub-id pub-id-type="pmid">36063827</pub-id>
</element-citation><mixed-citation id="mc-CR30" publication-type="journal">Billard MN, Bont LJ (2023) Quantifying the RSV immunity debt following COVID-19: a public health matter. Lancet Infect Dis 23:3&#x02013;5<pub-id pub-id-type="pmid">36063827</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR31"><label>31.</label><citation-alternatives><element-citation id="ec-CR31" publication-type="journal"><person-group person-group-type="author"><name><surname>Berikopoulou</surname><given-names>MM</given-names></name><name><surname>Dessypris</surname><given-names>N</given-names></name><name><surname>Kalogera</surname><given-names>E</given-names></name><etal/></person-group><article-title>Epidemiology of respiratory syncytial virus in hospitalized children before, during and after the COVID-19 lockdown restriction measures in Greece</article-title><source>Epidemiol Infect</source><year>2024</year><pub-id pub-id-type="doi">10.1017/S0950268824000724</pub-id><pub-id pub-id-type="pmid">38736253</pub-id>
</element-citation><mixed-citation id="mc-CR31" publication-type="journal">Berikopoulou MM, Dessypris N, Kalogera E et al (2024) Epidemiology of respiratory syncytial virus in hospitalized children before, during and after the COVID-19 lockdown restriction measures in Greece. Epidemiol Infect. 10.1017/S0950268824000724<pub-id pub-id-type="pmid">38736253</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR32"><label>32.</label><citation-alternatives><element-citation id="ec-CR32" publication-type="journal"><person-group person-group-type="author"><name><surname>Hoyer</surname><given-names>EA</given-names></name><name><surname>Joseph</surname><given-names>M</given-names></name><name><surname>Dunn</surname><given-names>J</given-names></name><etal/></person-group><article-title>Increasing incidence of Streptococcus anginosus group intracranial infections associated with sinusitis, otitis media, and mastoiditis in children</article-title><source>Pediatr Infect Dis J</source><year>2024</year><volume>43</volume><fpage>e261</fpage><lpage>e267</lpage><pub-id pub-id-type="doi">10.1097/INF.0000000000004346</pub-id><pub-id pub-id-type="pmid">38621168</pub-id>
</element-citation><mixed-citation id="mc-CR32" publication-type="journal">Hoyer EA, Joseph M, Dunn J et al (2024) Increasing incidence of Streptococcus anginosus group intracranial infections associated with sinusitis, otitis media, and mastoiditis in children. Pediatr Infect Dis J 43:e261&#x02013;e267. 10.1097/INF.0000000000004346<pub-id pub-id-type="pmid">38621168</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR33"><label>33.</label><citation-alternatives><element-citation id="ec-CR33" publication-type="journal"><person-group person-group-type="author"><name><surname>Troy</surname><given-names>E</given-names></name><name><surname>Sillau</surname><given-names>S</given-names></name><name><surname>Bernard</surname><given-names>TJ</given-names></name><name><surname>Rao</surname><given-names>S</given-names></name></person-group><article-title>Incidence and clinical outcomes of Streptococcus anginosus in acute complicated sinusitis: a pediatric cohort</article-title><source>J Pediatric Infect Dis Soc</source><year>2021</year><volume>10</volume><fpage>168</fpage><lpage>171</lpage><pub-id pub-id-type="doi">10.1093/jpids/piz098</pub-id><pub-id pub-id-type="pmid">31925948</pub-id>
</element-citation><mixed-citation id="mc-CR33" publication-type="journal">Troy E, Sillau S, Bernard TJ, Rao S (2021) Incidence and clinical outcomes of Streptococcus anginosus in acute complicated sinusitis: a pediatric cohort. J Pediatric Infect Dis Soc 10:168&#x02013;171. 10.1093/jpids/piz098<pub-id pub-id-type="pmid">31925948</pub-id>
</mixed-citation></citation-alternatives></ref></ref-list></back></article>